Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib Combined With Envafolimab in Metastatic GIST With KIT Exon 17 Mutations
NCT07559864Phase 2Recruiting
- Start
- Jul 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules, Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of envafolimab, regorafenib in gastrointestinal stromal tumor (GIST). Started Jul 2025; status: recruiting.
02
Drugs
envafolimabregorafenib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT07559864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07559864.